Skip to Content

Join the 'Cyramza' group to help and get support from people like you.

Cyramza News

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Gleevec, Colorectal Cancer, Lung Cancer, Brain Tumor, Votrient, Avastin, Tarceva, Melanoma, Skin Cancer, Nausea/Vomiting - Chemotherapy Induced, Tasigna, Ovarian Cancer, Sutent, Endometrial Cancer, Sprycel, Afinitor, Herceptin

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Colorectal Cancer, Lung Cancer, Isotretinoin, Rituxan, Claravis

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Prostate Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Colorectal Cancer, Lung Cancer, Renal Cell Carcinoma, Rituxan

FDA Approves Cyramza (Ramucirumab) for Use with FOLFIRI in Second-Line Treatment of Metastatic Colorectal Cancer

Posted 24 Apr 2015 by Drugs.com

INDIANAPOLIS, April 24, 2015 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for Cyramza (ramucirumab). Cyramza (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. "Cyramza now has approvals in advanced or metastatic forms of three of the world's most common and deadly cancers – gastric, non-small cell lung, and colorectal – with four FDA approvals received in just over a year," said Sue Mahony, Ph.D., senior vice president and president, Lilly Oncology. "This progress is encouraging and supports our ongoing development program for Cyramza. ... Read more

Related support groups: Cancer, Colorectal Cancer, Cyramza, Ramucirumab

FDA Expands Approved use of Cyramza to Treat Aggressive Non-Small Cell Lung Cancer

Posted 12 Dec 2014 by Drugs.com

The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues of the lung. The National Cancer Institute estimates that 224,210 Americans will be diagnosed and 159,260 will die from lung cancer in 2014. Cyramza works by blocking the blood supply that fuels tumor growth. The drug is intended for patients whose tumor has grown (progressed) during or following treatment with platinum-based chemotherapy, and it is to be used in combination with docetaxel, another type of chemotherapy. “Today’s approval is the third indication that Cyramza has received in 2014,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Th ... Read more

Related support groups: Non-Small Cell Lung Cancer, Cyramza, Ramucirumab

Cyramza Approval Expanded to Include Non-Small Lung Cancer

Posted 12 Dec 2014 by Drugs.com

FRIDAY, Dec. 12, 2014 – U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small cell lung cancer (NSCLC), the agency said Friday. NSCLC, the most common form of lung cancer, will be diagnosed in an estimated 224,000 Americans this year, and about 159,000 Americans will die from it, the FDA said, citing U.S. National Cancer Institute projections. Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs. Cyramza was first approved in April to treat advanced cancers of the stomach or gastrointestinal tract, and approval was widened in November to include advanced gastric cancers. Clinical side effects have included a drop in germ-fighting white blood cells, inflammation of the mouth's lining, severe bleeding, ... Read more

Related support groups: Non-Small Cell Lung Cancer, Cyramza, Ramucirumab

FDA Approves Cyramza (ramucirumab) in Combination with Paclitaxel for Advanced Gastric Cancer after Prior Chemotherapy

Posted 5 Nov 2014 by Drugs.com

INDIANAPOLIS, Nov. 5, 2014 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. Cyramza now has two FDA approvals for these patients. Today's announcement follows the April approval of Cyramza as a single agent – the first approval of a treatment in the U.S. for patients in this setting. "This FDA approval of Cyramza represents another milestone for people battling this devastating and difficult-to-treat disease," said Richard Gaynor, M.D., senior vice president, product development and medical affairs for Lilly O ... Read more

Related support groups: Stomach Cancer, Paclitaxel, Gastric Cancer, Cyramza, Ramucirumab

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Cephalexin, Clindamycin, Penicillin, Methotrexate, Azithromycin, Bactrim, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

Ask a Question

Further Information

Related Condition Support Groups

Gastric Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Stomach Cancer

Cyramza Patient Information at Drugs.com